

Interface and Formulary Update - Issue 36

June 2025

Key messages from **June 2025 TAG meeting** - (ratified by Medicines Optimisation Programme Board)

Commissioning Review - Tirzepatide for managing overweight and obesity - **updates**

- [Prescribing Guidance document](#) and [Netformulary](#) updated to reflect availability in primary care from 23rd June 2025
- **RED** - Only available via specialist weight management services for patients with a BMI of at least 35 and at least one weight-related comorbidity as per [TA1026](#)
- **GREEN** - Only available in primary care for patients who have at least 4 of the 5 qualifying health conditions (type 2 DM, high blood pressure, heart disease, obstructive sleep apnoea and abnormal blood fats) plus a BMI of at least 40 (BMI to be adjusted for ethnicity)
- **BLACK** - Not commissioned for any other weight / obesity patient cohorts

Formulary Review - Ketamine use in palliative care - **RED Hospital / Specialist Only**

Formulary Review - Latanoprost and Netarsudil (Roclanda) eye drops for previously treated primary open-angle glaucoma or ocular hypertension - **AMBER INITIATE. Specialist will prescribe initial supply**

Formulary Review - Sublingual Immunotherapy (SLIT) - Acarizax application

- **AMBER INITIATE** for use in people aged 12 to 65 years with allergic rhinitis. **Specialist Allergy Clinic to provide medication for the first month, notify GP of prescribing recommendations and to arrange follow-up and review.**
- **BLACK** for use in house dust mite allergic asthma in adults

Formulary Review - Vibegron for treating symptoms of overactive bladder syndrome as per [TA999](#)

- **GREEN** - can be initiated and prescribed in any care setting, within licensed indications
- Updated pathway [published here](#)

Formulary Review - Naldemedine for opioid-induced constipation as per [TA651](#)

- **GREEN** - can be initiated and prescribed in any care setting, within licensed indications

Formulary Review - Ritlecitinib for severe alopecia areata in adults and adolescents 12 years of age and older as per [TA958](#)

- **RED - Hospital Only**

Formulary and Guidance Updates

Formulary and Guidance Updates

- **Lansoprazole orodispersible tablets** – generic preparation added to formulary for use in adult patients who require a PPI and have administration via an enteral tube. Not licensed for use in children.
- **Bicalutamide 50mg and 150mg tablets** – both strengths added to formulary with **ADVICE** classification
- [Traffic light classifications](#)
- [Use of Biosimilars](#)

Shared Care Updates

Melatonin for sleep disorders in children

- Routine updates including addition of Ceyesto 1mg/ml oral solution for restricted group
- Document [published here](#)

Lithium for patients within adult services

- **Shared Care Level 1** classification recommended
- Document [published here](#)

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

HOSPITAL / SPECIALIST ONLY	TA1051 – April 2025 - Efanesoctocog alfa (Altuvect®) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over
	TA1053 – April 2025 - Cladribine (Mavenclad®) for treating active relapsing forms of multiple sclerosis
	TA1054 – April 2025 - Ruxolitinib (Jakavi®) for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over
	TA1055 – April 2025 - Rucaparib (Rubraca®) for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
	TA1059 – May 2025 - Brentuximab vedotin (Adcetris®) in combination for untreated stage 3 or 4 CD30-positive Hodgkin Lymphoma
	TA1060 – May 2025 - Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
	TA1062 – May 2025 - Erdafitinib (Balversa®) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
	TA1063 – May 2025 - Capivasertib (Truqap®) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment
	TA1064 – May 2025 - Dostarlimab (Jemperli®) with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
	TA1065 – May 2025 - Nivolumab (Opdivo®) plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
	HST8 – October 2018, updated April 2025 - Burosumab (Crysvita®) for treating X-linked hypophosphataemia in children and young people
	HST33 – April 2025 - Leniolisib (Joenja®) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over
NICE-APPROVED	TA1057 – April 2025 - Relugolix–estradiol–norethisterone (Ryeqo®) for treating symptoms of endometriosis
BLACK	HST32 – April 2025 - Olipudase alfa (Xenpozyme®) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B
	TA1052 – April 2025 - Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)
	TA1058 – April 2025 - Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)
	TA1061 – May 2025 - Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)
AMBER INITIATE	TA753 – December 2021, updated May 2025 - Cenobamate (Ontozry®) for treating focal onset seizures in epilepsy
NOTED – NO CHANGE TO EXISTING ARRANGEMENTS	TA1056 – April 2025 - Molnupiravir (Lagevrio®) for treating COVID-19
	TA878 – March 2023, updated May 2025 - Nirmatrelvir plus ritonavir (Paxlovid®), Sotrovimab (Xevudy®) and Tocilizumab (RoActemra®) for treating COVID-19

Useful Information

Next TAG meeting	Wednesday 2nd July 2025
Deadline for agenda submissions	Tuesday 24th June 2025

Netformulary	Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)
Knowledge NoW – Medicines Optimisation Home Page	Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)
TAG Guidance	Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)
Shared Care Agreements	Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)
Pathways and Prescribing Guidance	Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)
Practice Support	Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)
Useful Links	Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)

- **Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates**
- If you have any interface or formulary queries, please send to the inbox - nwicb.medsqueries@nhs.net